Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
D Khanna, CP Denton, CJF Lin, JM Van Laar… - Annals of the …, 2018 - ard.bmj.com
Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc)
in a phase II study. Methods Patients with SSc were treated for 48 weeks in an open-…
in a phase II study. Methods Patients with SSc were treated for 48 weeks in an open-…
Tocilizumab prevents progression of early systemic sclerosis–associated interstitial lung disease
D Roofeh, CJF Lin, J Goldin, GH Kim… - Arthritis & …, 2021 - Wiley Online Library
Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …
Long-term safety and efficacy of tocilizumab in early systemic sclerosis–interstitial lung disease: open-label extension of a phase 3 randomized controlled trial
Rationale: Tocilizumab, an anti–IL-6 receptor antibody, had no statistically significant effect
on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic …
on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic …
[HTML][HTML] Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial
…, J McBride, CM Rosenberger, CJF Lin… - Critical Care …, 2022 - journals.lww.com
OBJECTIVES: To explore candidate prognostic and predictive biomarkers identified in
retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, …
retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, …
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in …
Objectives American College of Rheumatology Composite Response Index in Systemic
Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in …
Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in …
Safety and efficacy of tocilizumab 4 or 8 mg/kg in hospitalized patients with moderate to severe coronavirus disease 2019 pneumonia: a randomized clinical trial
…, SC Thornton, W Stubbings, CJF Lin… - Open Forum …, 2022 - academic.oup.com
Background Tocilizumab, an interleukin 6 receptor (IL-6R) antagonist monoclonal antibody,
has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but …
has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but …
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort
Objectives To explore prognostic and predictive markers of SSc-associated interstitial lung
disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-…
disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-…
Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting
…, A Balasubramanian, N Pannacciulli, CJF Lin… - The Journal of …, 2018 - jrheum.org
Objective. Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD)
to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, …
to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, …
[HTML][HTML] Biomarkers of fibrosis, inflammation, and extracellular matrix in the Phase 3 trial of tocilizumab in systemic sclerosis
…, C Schiffman, J Jiang, TR Ramalingam, CJF Lin… - Clinical …, 2023 - Elsevier
Drug development for systemic sclerosis (SSc) benefits from understanding the relationship
between disease and circulating biomarkers to enable activities such as patient stratification …
between disease and circulating biomarkers to enable activities such as patient stratification …